Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GDA-201 |
Synonyms | |
Therapy Description |
GDA-201 is composed of ex vivo activated donor natural killer cells, which may have persistent anti-tumor activity (Blood (2019) 134 (Supplement_1): 777). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GDA-201 | GDA-201 is composed of ex vivo activated donor natural killer cells, which may have persistent anti-tumor activity (Blood (2019) 134 (Supplement_1): 777). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05296525 | Phase Ib/II | GDA-201 | Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | Terminated | USA | 0 |